First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts

BACKGROUND: The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has been transformed by targeted therapies with tyrosine kinase inhibitors (TKI) and more recently by the incorporation of immune checkpoint inhibitors (ICI). Today, a spectrum of single agent TKI to TKI/ICI a...

Descripción completa

Detalles Bibliográficos
Autores principales: Aeppli, S., Schmaus, M., Eisen, T., Escudier, B., Grünwald, V., Larkin, J., McDermott, D., Oldenburg, J., Porta, C., Rini, B.I., Schmidinger, M., Sternberg, C.N., Rothermundt, C., Putora, P.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815472/
https://www.ncbi.nlm.nih.gov/pubmed/33460963
http://dx.doi.org/10.1016/j.esmoop.2020.100030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815472/
https://www.ncbi.nlm.nih.gov/pubmed/33460963
http://dx.doi.org/10.1016/j.esmoop.2020.100030

Ejemplares similares